Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 11-20 of 67 for

Edit search filters
  1. Testing The Use Of Chemotherapy After Surgery For High-Risk Pancreatic Neuroendocrine Tumors

    Scottsdale/Phoenix, AZ, Rochester, MN

  2. Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery

    Rochester, MN

  3. A Study of the Safety and Effectiveness of TH-302 Combined with Gemcitabine and Compared with Gemcitabine Alone for Previously Untreated Patients with Pancreatic Adenocarcinoma

    Scottsdale/Phoenix, AZ, Rochester, MN

  4. Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss

    Scottsdale/Phoenix, AZ, Rochester, MN

  5. Protein-bound Paclitaxel, Cisplatin, And Gemcitabine (GCN) Combined With Tumor Treatment Fields (TTF) In Patients With Metastatic Pancreatic Adenocarcinoma

    Jacksonville, FL, Rochester, MN

  6. Study Of Daraxonrasib (RMC-6236) In Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. A Study Combining Tofacitinib with Gemcitabine for the Treatment of Pancreas Cancer in Patients who are Losing Weight

    Rochester, MN

  8. Lutetium 177Lu-Edotreotide Versus Best Standard Of Care In Well-differentiated Aggressive Grade-2 And Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (COMPOSE)

    Rochester, MN

  9. A Study of GDC-0449 and Erlotinib Hydrochloride, with or without Gemcitabine Hydrochloride for Treating Patients with Metastatic Pancreatic Cancer or Solid Tumors that cannot be Removed by Surgery

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  10. Evaluation Of PCLs Using Three EUS-FNA Needles

    Scottsdale/Phoenix, AZ, Jacksonville, FL

.

Mayo Clinic Footer